CA2466497A1 - Protease assay for therapeutic drug monitoring - Google Patents

Protease assay for therapeutic drug monitoring Download PDF

Info

Publication number
CA2466497A1
CA2466497A1 CA002466497A CA2466497A CA2466497A1 CA 2466497 A1 CA2466497 A1 CA 2466497A1 CA 002466497 A CA002466497 A CA 002466497A CA 2466497 A CA2466497 A CA 2466497A CA 2466497 A1 CA2466497 A1 CA 2466497A1
Authority
CA
Canada
Prior art keywords
biological sample
bio
drug
active ingredient
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002466497A
Other languages
English (en)
French (fr)
Inventor
Sergei Gulnik
Betty Yu
John W. Erickson
Martin Markowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Rockefeller University
Aaron Diamond AIDS Research Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2466497A1 publication Critical patent/CA2466497A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002466497A 2001-11-08 2002-11-08 Protease assay for therapeutic drug monitoring Abandoned CA2466497A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33111701P 2001-11-08 2001-11-08
US60/331,117 2001-11-08
PCT/EP2002/012631 WO2003040390A2 (en) 2001-11-08 2002-11-08 Protease assay for therapeutic drug monitoring

Publications (1)

Publication Number Publication Date
CA2466497A1 true CA2466497A1 (en) 2003-05-15

Family

ID=23292681

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002466497A Abandoned CA2466497A1 (en) 2001-11-08 2002-11-08 Protease assay for therapeutic drug monitoring

Country Status (8)

Country Link
US (1) US7320878B2 (de)
EP (1) EP1446498B1 (de)
JP (1) JP2005513420A (de)
AT (1) ATE389029T1 (de)
CA (1) CA2466497A1 (de)
DE (1) DE60225587T2 (de)
ES (1) ES2302860T3 (de)
WO (1) WO2003040390A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014030A1 (en) * 2002-07-18 2004-01-22 Lili Arabshahi Enzymatic assay of HIV protease inhibitors
KR20060092254A (ko) * 2003-09-23 2006-08-22 라이트 사이언시즈 코포레이션 표적화된 ｐｄｔ 제제의 선택성을 증진시키는 표적 결합에의해 활성화된 일중항 산소 감광제
US20060199221A1 (en) * 2005-03-07 2006-09-07 Samad Talebpour Correction for temperature dependence assays
WO2007079392A2 (en) * 2005-12-30 2007-07-12 The Trustees Of Columbia University In The City Of New York Real-time assays of neuro-humoral to assess cardiovascular stress
US8185319B2 (en) * 2006-01-19 2012-05-22 Novx Systems Canada Inc. Method of compensation of dose-response curve of an assay for sensitivity to perturbing variables
GB201402132D0 (en) * 2014-02-07 2014-03-26 South African Nuclear Energy A method of producing ethylenedicysteine deoxyglucosamine (ECDG) or a salt thereof and its application in a kit

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1185881A (en) 1982-02-01 1985-04-23 Jacques Degelaen ENZYMATIC PROCESS FOR THE DETERMINATION OF .beta.-LACTAM ANTIBIOTICS
DE3531778A1 (de) 1985-09-06 1987-03-12 Behringwerke Ag Verfahren zur bestimmung von proteaseinhibitoren
EP0428000A1 (de) 1989-11-03 1991-05-22 Abbott Laboratories Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
US5843946A (en) 1992-08-25 1998-12-01 G.D. Searle & Co. α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5576177A (en) 1994-03-09 1996-11-19 St. Jude Children's Research Hospital Bioassay for reverse transcriptase inhibitors
CN1209875A (zh) 1996-01-26 1999-03-03 维科公司 根据人类hiv病毒株的表型药物敏感性控制hiv阳性病人化疗的方法
AU732255B2 (en) 1996-01-29 2001-04-12 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
JP3768304B2 (ja) 1996-10-07 2006-04-19 株式会社松井製作所 冷媒設備用のバルブ
EP0972071A4 (de) * 1997-03-07 2004-04-21 Tropix Inc Versuchsanordnung für proteaseinhibitoren
US6017723A (en) * 1998-03-27 2000-01-25 Long Island Jewish Medical Center Method for isolating inhibitors of protease activity
CA2228821A1 (en) 1998-04-16 1999-10-16 Zhibo Gan Pin method for measuring bioactive substance
CA2336160C (en) 1998-06-23 2015-02-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of compounds for treating hiv
AU2001233513A1 (en) 2000-02-04 2001-08-14 K.U. Leuven Research And Development Hiv-1 resistance assay
DE60135366D1 (de) 2000-04-18 2008-09-25 Virco Bvba Methode zur bestimmung der resistenz gegen medikamente
EP1328806A2 (de) 2000-09-15 2003-07-23 Virco N.V. System und methode zur optimierung der medikamentösen therapie in der behandlung von krankheiten
IL155780A0 (en) 2000-11-10 2003-12-23 Bioalliance Pharma Novel method for analysing phenotypic characteristics of human imunodeficiency virus (hiv)

Also Published As

Publication number Publication date
DE60225587T2 (de) 2009-04-02
EP1446498B1 (de) 2008-03-12
WO2003040390A3 (en) 2003-09-25
ATE389029T1 (de) 2008-03-15
WO2003040390A2 (en) 2003-05-15
US7320878B2 (en) 2008-01-22
US20050221286A1 (en) 2005-10-06
JP2005513420A (ja) 2005-05-12
DE60225587D1 (de) 2008-04-24
ES2302860T3 (es) 2008-08-01
EP1446498A2 (de) 2004-08-18

Similar Documents

Publication Publication Date Title
Matayoshi et al. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer
Figueiredo et al. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol
Yu et al. Selective and facile assay of human immunodeficiency virus protease activity by a novel fluorogenic reaction
US8592161B2 (en) Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
US20060035249A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
JP2008022861A (ja) ヒト免疫不全ウイルス（ｈｉｖ）の表現型特性の新規な分析法
EP1446498B1 (de) Protease assay zur kontrolle medikamentöser therapie
CN106661607A (zh) 酶抑制剂耐药性检测方法与装置
Lindsten et al. Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity
WO2000078996A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
Knops et al. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors
Han et al. A high-throughput assay for HIV-1 integrase 3′-processing activity using time-resolved fluorescence
CA2435507A1 (en) Improved assay for protein tyrosine phosphatases
US20020064838A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU2001290923A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU2002363346A1 (en) Protease assay for therapeutic drug monitoring
US6869759B1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
Iga et al. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation
Majerová-Uhlíková et al. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants
US7108988B2 (en) Methods of identifying agents for inhibiting lentivirus replication
US8036861B2 (en) Method and means for determining the replication rate of a viral population
US20050158709A1 (en) Methods for determinging the influence of protein binding on antiretroviral activity
Kwan et al. A fluorescence resonance energy transfer-based binding assay for characterizing kinase inhibitors: Important role for C-terminal biotin tagging of the kinase
US20070269797A9 (en) Method for analysis of the phenotypic characteristics of the human immunodeficiency virus (HIV)
Shabangu Structural and enzymatic studies of HIV-1 subtype C protease

Legal Events

Date Code Title Description
FZDE Discontinued